TECHNE CORPORATION
HomeCompany NewsFinancial InformationAbout TechneMap - DirectionsProductsContact Us

Segment Results - 1st Quarter Fiscal Year 2009

TECHNE CORPORATION AND SUBSIDIARIES
(in thousands of $’s, except per share data)
Fiscal 2009 Increase(Decrease) From Fiscal 2008
First Quarter Percent Of Sales First Quarter
Sales 69,324 100% 11,337
Cost of sales 13,086 19% 982
Gross margin 56,238 81% 10,355
       
Gross margin percentage 81.1%    
       
SG&A expense 8,840 13% 750
R&D expense 5,910 8% 729
Amortization expense 240 - (48)
Interest income (2,887) (4%) 111
Other non-operating ex., net 1,187 2% 618
  13,290 19% 2,160
Earnings before income taxes 42,948 62% 8,195
Income taxes 14,355 21% 2,674
  28,593 41% 5,521
       
Diluted earnings per share .74    
Weighted average diluted shares outstanding 38,747    

Back to Top
HEMATOLOGY DIVISION
(in thousands of $’s)
Fiscal 2009 Increase(Decrease)From Fiscal 2008
First Quarter Percent Of Sales First Quarter
Sales 4,246 100% 589
Cost of sales 2,369 56% 108
Gross margin 1,877 44% 481
       
Gross margin percentage 44.2%    
       
SG&A expense 436 10% (31)
R&D expense 193 4% 14
Interest, net (102) (2%) 18
  527 12% 1
Pretax result 1,350 32% 480

Back to Top
BIOTECHNOLOGY DIVISION (1)
(in thousands of $’s)

Fiscal 2009 Increase(Decrease) From Fiscal 2008
First Quarter Percent Of Sales First Quarter
Sales 53,899 100% 8,571
Intersegment sales (7,762)   (1,315)
  46,137   7,256
       
Cost of sales 10,247 19% 1,250
Intersegment sales (7,461)   (1,287)
  2,786   (37)
       
Gross margin 43,351 81% 7,293
       
Gross margin percentage 81.0%    
       
SG&A expense 5,141 10% 517
R&D expense 5,717 11% 715
Amortization expense 240 -- (48)
Interest, net (1,084) (2%) 173
Exchange loss/(gain) (2) -- (36)
  10,012 19% 1,321
Pretax result 33,339 62% 5,972

(1) Includes R&D Systems' Biotechnology Division, BiosPacific, Inc. and R&D China

Back to Top

R&D SYSTEMS EUROPE
(in thousands of £'s) 

Fiscal 2009 Increase(Decrease) From Fiscal 2008
First Quarter Percent Of Sales First Quarter
Sales 10,175 100% 2,570
Cost of sales 4,260 42% 805
Gross margin 5,915 58% 1,765
Gross margin percentage 58.1%
SG&A expense 1,224 12% 110
Interest income (790) (8%) (107)
Exchange loss/(gain) 260 3% 356
694 7% 359
Pretax result 5,221 51% 1,406

Back to Top
R&D SYSTEMS EUROPE
(in thousands of $’s)
Fiscal 2009 Increase(Decrease) From Fiscal 2008
First Quarter Percent Of Sales First Quarter
Sales 18,941 100% 3,492
Cost of sales 7,931 42% 911
Gross margin 11,010 58% 2,581
       
Gross margin percentage 58.1%    
       
SG&A expense 2,283 12% 21
Interest income (1,471) (8%) (84)
Exchange loss 476 3% 674
  1,288 7% 611
Pretax result 9,722 51% 1,970

Back to Top
CORPORATE AND OTHER (2)
(in thousands of $’s)
Fiscal 2009 Increase(Decrease) From Fiscal 2008
First Quarter First Quarter
Interest income 230 (4)
Rental income 99 32
  329 28
     
SG&A expense 980 243
Other-Building expenses 553 9
Other-Equity Investment losses 259 3
  1,792 255
Pretax result (1,463) (227)

Back to Top

(2) Unallocated corporate expenses and Techne’s share of losses by Hemerus Medical, LLC
Back to Top



Home - Company News - Financial Information - About TECHNE - Map/Directions - Products - Contact Us

TECHNE CORPORATION
614 McKinley Place N.E.    Minneapolis, MN 55413-2610
Phone: (612)379-8854   Fax: (612)379-6580
e-mail: techinfo@techne-corp.com


* Up to a 15 minute delay on Market Overview. Please consult your financial advisor for an up-to-minute quote.
Quote provided by Barchart.com.